Lercanidipine Mylan 10mg, 20mg Film-Coated Tablets

  • Name:

    Lercanidipine Mylan 10mg, 20mg Film-Coated Tablets

  • Company:
    info
  • Active Ingredients:

    Lercanidipine Hydrochloride

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 15/07/15

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 30/1/2018
print

Print ViewKeyword Search SmPC

Gerard Laboratories

Gerard Laboratories

Company Products

Medicine NameActive Ingredients
Medicine Name Abacavir/Lamivudine Mylan 600 mg/300 mg film-coated tablets Active Ingredients Abacavir hydrochloride, Lamivudine
Medicine Name Agerdex 1mg Film Coated Tablets Active Ingredients Anastrozole
Medicine Name Agomelatine Mylan 25 mg film-coated tablets Active Ingredients Agomelatine
Medicine Name Amisulpride 50mg & 200mg Tablets Active Ingredients Amisulpride
Medicine Name Amlodipine Mylan 5mg & 10mg Tablets Active Ingredients Amlodipine besilate
Medicine Name Amlodipine/Valsartan Mylan 5mg/80mg, 5mg/160mg, 10mg/160mg film-coated tablets Active Ingredients Amlodipine besilate, Valsartan
Medicine Name Areloger 7.5mg & 15mg Tablets Active Ingredients Meloxicam
Medicine Name Aripil 5mg & 10mg Film-coated Tablets Active Ingredients Donepezil Hydrochloride
Medicine Name Atenetic 50/12.5mg & 100/25mg Film - coated Tablets Active Ingredients Atenolol, Chlortalidone
Medicine Name Atorvastatin Mylan 10 mg, 20 mg, 40 mg & 80 mg film-coated tablets Active Ingredients Atorvastatin calcium trihydrate
Medicine Name Atovaquone/Proguanil Hydrochloride 250 mg/100 mg film-coated tablets Active Ingredients Atovaquone, Proguanil Hydrochloride
Medicine Name Azromax 250mg Film-coated tablets Active Ingredients Azithromycin monohydrate
Medicine Name Baclopar Tablets 10 mg Active Ingredients Baclofen
Medicine Name Bisoprolol Mylan Active Ingredients Bisoprolol Fumarate
Medicine Name Brabio 20mg/ml solution for injection, pre-filled syringe Active Ingredients Glatiramer Acetate
Medicine Name Brabio 40mg/ml solution for injection, pre-filled syringe Active Ingredients Glatiramer Acetate
Medicine Name Cifloxager 250 mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Cifloxager 500 mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciprager 10mg & 20mg Film Coated Tablets Active Ingredients citalopram hydrobromide
Medicine Name Ciprager 40mg Film Coated Tablets Active Ingredients citalopram hydrobromide
Medicine Name Ciprofloxacin Mylan 2mg/1ml solution for infusion Active Ingredients Ciprofloxacin
Medicine Name Clopidogrel Mylan 75 mg film-coated tablets Active Ingredients clopidogrel hydrochloride
Medicine Name Darunavir Mylan 800 mg film-coated tablets Active Ingredients darunavir ethanolate
Medicine Name Depreger 50mg & 100mg Film-Coated Tablets Active Ingredients sertraline hydrochloride
Medicine Name Diaclide MR 30 mg Modified-release Tablets Active Ingredients Gliclazide
1 - 0 of 117 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 30 January 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4. CLINICAL PARTICULARS

4.2 Posology and method of administration

Method of administration
For oral use.

Precautions to be taken before handling or administering the medicinal product:

Treatment should be preferably administered in the morning at least 15 minutes before breakfast.


4.4 Special warnings and precautions for use

Sick-sinus syndrome
Special care should be exercised when lercanidipine is used in patients with sick sinus syndrome (if without a pacemaker is not in situ).

4.5 Interaction with other medicinal products and other forms of interaction

Interaction studies have only been performed in adults.

10. DATE OF REVISION OF THE TEXT

July 2015September 2017

Updated on 30 January 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 15 July 2015 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to instructions about missed dose
  • Change to instructions about overdose
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to further information section
  • Change to date of revision
  • Change to appearance of the medicine
  • Addition of information on reporting a side effect.

Updated on 15 July 2015 SmPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4 - Clinical particulars
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Updated text highlighted in red.

3. PHARMACEUTICAL FORM

Film-coated tablet.

10mg:
Yellowish brown, round, biconvex film-coated tablet debossed with “LR over 1” on one side of the tablet and with a deep score line on the other side
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

20mg:
Pink, round, biconvex film-coated tablets, debossed with “LR over 2” on one side of the tablet and with a deep score line on the other side.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.



4.1 Therapeutic indications

Lercanidipine Mylan is indicated in adults for the treatment of mild to moderate essential hypertension.


4.2 Posology and method of administration

Paediatric population
The safety and efficacy of lercanidipine in children up to 18 years have not been established. No data are available

4.4 Special warnings and precautions for use

Following headings added:
Sick-sinus syndrome
Left ventricular dysfunction and ischaemic heart disease
Alcohol
Inducers of CYP3A4
Lercanidipine Mylan contains lactose

Section added:
Paediatric population
The safety and efficacy of lercanidipine has not been demonstrated in children.


4.5 Interaction with other medicinal products and other forms of interaction

Following headings added:
Inhibitors of CYP3A4
Ciclosporin
Grapefruit juice
Midazolam
Substrates of CYP3A4
Inducers of CYP3A4
Metoprolol
Fluoxetine
Cimetidine
Digoxin
Simvastatin
Warfarin
Diuretics and ACE inhibitors
Alcohol

Section added:
Paediatric population
Interaction studies have only been performed in adults.

4.6 Fertility, pPregnancy and lactation

Breast-feeding
It is unknown whether lercanidipine/metabolites are excreted in human milk. A risk in the newborns/infants cannot be excluded. Lercanidipine Mylan is contraindicated during breastfeeding (see section 4.3)

Fertility
No clinical data are available with lercanidipine. Reversible biochemical changes in the head of spermatozoa which can impair fecundation have been reported in some patients treated by channel blockers. In cases where repeated in-vitro fertilisation is unsuccessful and where another explanation cannot be found, the possibility of calcium channel blockers as the cause should be considered.


4.7 Effects on ability to drive and use machines

Lercanidipine has minor influence on the ability to drive and use machines.. However, caution should be exercised because dizziness, asthenia, fatigue and rarely somnolence may occur.

4.8 Undesirable effects

Very common (1/10)
Common (1/100 to <1/10)
Uncommon (1/1,000 to <1/100)
Rare (1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (cannot be estimated from the available data)
Within each frequency grouping the observed adverse reactions are presented in order of decreasing seriousness.

Nervous system disorders:
Rare: Somnolence
Very rare: Syncope

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2. Tel: +353 1 6764971; Fax: +353 1 6762517; website:
www.hpra.ie; e-mail: medsafety@hpra.ie.

4.9 Overdose

 

In the post-marketing experience, some cases of overdose were reported (from 40 up to 800 mg of lercanidipine , including reports of suicide attempt).

Symptoms
As with other dihydropyridines, overdosage might be expected to cause excessive peripheral vasodilatation. Symptoms associated to overdose include  marked hypotension and reflex tachycardia.


5.1  Pharmacodynamic properties

following headings added:
Mechanism of action
Pharmacodynamic effects
Clinical efficacy and safety

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for human based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.

6.5 Nature and contents of container

Cold form Al/OPA/PVC/Al blister packs containing 7, 14, 28, 35, 50, 56, 98 and 100 tablets.

HDPE bottle with opaque polypropylene cap with dessicant containing 500 and 1000 tablets.

Not all pack sizes may be marketed.

10. DATE OF REVISION OF THE TEXT

July 2015




(internal reference: UK/H/3812/IB/010)

Updated on 15 July 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 15 December 2014 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 3 December 2014 PIL

Reasons for updating

  • New PIL for new product